FDA resuming China lab inspections could benefit Amicus, BeiGene, Barron’s says
The Fly

FDA resuming China lab inspections could benefit Amicus, BeiGene, Barron’s says

Now that the FDA is resuming drug lab inspections in China three years after the pandemic started, biotech stocks such as Amicus (FOLD), BeiGene (BGNE), Novartis (NVS), and Coherus BioSciences (CHRS) could benefit, writes Josh Nathan-Kazis in Barron’s. Amicus’ Pompe drug was set to be manufactured by Chinese company WuXi Biologics before the FDA delayed its review of the drug because the agency’s inspectors could not visit the WuXi facility in China, while a new cancer treatment from BeiGene and Novartis was also delayed, the author says, noting that another cancer drug from Coherus was also in limbo. Reference Link

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on FOLD:

Related Articles
TheFlyBeiGene initiated with an Outperform at JMP Securities
TheFlyBeiGene shares new Tevimbra data at ESMO 2024
TheFlyBeiGene announces FDA grants Fast Track Designation to BGB-16673
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App